Swiss Primary Sclerosing Cholangitis Cohort Study
1 other identifier
observational
120
1 country
21
Brief Summary
Research project in which biological material is sampled and health-related personal data is further used and collected. Coded data are used.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2017
Longer than P75 for all trials
21 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 28, 2017
CompletedFirst Submitted
Initial submission to the registry
May 8, 2017
CompletedFirst Posted
Study publicly available on registry
May 10, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
August 19, 2025
August 1, 2025
13.8 years
May 8, 2017
August 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Disease course
Observing disease course
3 years
Disease features
Observing disease features in Swiss population and see if they are similar to other countries'
3 years
Response to treatment
Observing response to treatment
3 years
Overall survival
Observing overall survival
3 years
Transplantation-free survival rate
Observing transplantation-free survival rate
3 years
Eligibility Criteria
PSC patients living in Switzerland of any age Patients diagnosed with PSC according to established criteria (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases). Only patients living in Switzerland are enrolled. Enrollment of minors is possible upon consent of legal guardian
You may qualify if:
- Patients diagnosed with PSC according to established criteria (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases) of any age. Patients not fulfilling such criteria but still diagnosed with PSC in a hepatology referral centre can be included
- patients living in Switzerland
You may not qualify if:
- N/A
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (21)
Fondazione Epatocentro Ticino
Lugano, Canton Ticino, 6900, Switzerland
Gastroenterologie und Hepatologie Clarunis - Universitäres Bauchzentrum Universitätsspital Basel
Basel, 4031, Switzerland
Universitäts-Kinderspital beider Basel UKBB, Gastroenterologie&Ernährung
Basel, 4031, Switzerland
Inselspital
Bern, 3010, Switzerland
Kinderklinik, INSELSpital, Universität Bern, Pädiatrische Gastroenterologie, Hepatologie und Ernährung
Bern, 3010, Switzerland
Spital Bülach
Bülach, 8180, Switzerland
Kantonsspital Graubünden
Chur, 7000, Switzerland
Hôpitaux Universitaires de Genève, Centre Suisse des Maladies du foie de l'Enfant- Département de l'Enfant et de l'Adolescent
Geneva, 1205, Switzerland
Hôpitaux Universitaires de Genève, Service de Gastroentérologie & Hépatologie, Département des Spécialités
Geneva, 1205, Switzerland
CHUV: Centre hospitalier universitaire vaudois
Lausanne, 1005, Switzerland
CHUV Département femme-mère-enfant
Lausanne, 1011, Switzerland
Kantonsspital Baselland
Liestal, 4410, Switzerland
Kinderspital Luzern LUKS, Pädiatrische Gastroenterologie
Lucerne, 6000, Switzerland
Luzerner Kantonsspital
Lucerne, 6000, Switzerland
EOC Ospedale Regionale di Lugano - Italiano
Lugano, 6900, Switzerland
Ostschweizer Kinderspital
Sankt Gallen, 9006, Switzerland
Kantonsspital St.Gallen
Sankt Gallen, 9007, Switzerland
Kantonsspital Winterthur
Winterthur, 8400, Switzerland
Pädiatrische Gastroenterologie Departement Kinder- und Jugendmedizin Kantonsspital Winterthur
Winterthur, 8400, Switzerland
Universitäts-Kinderspital Zürich - Eleonorenstiftung
Zurich, 8032, Switzerland
Universitätsspital Zürich
Zurich, 8091, Switzerland
Biospecimen
1. Serum (BD Vacutainer® SST II Advance) 2. RNA (PAXgene™ Blood RNA tube- 762165)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 8, 2017
First Posted
May 10, 2017
Study Start
February 28, 2017
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2030
Last Updated
August 19, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share